BSGM

ANALYST NOTE: BSGM (BioSig Technologies, Inc.) Date: 2026-06-13 Current Price: $6.10

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 10.4% (Extreme)

Analysis: As of the close on 2026-06-13, the structural setup for BSGM is not defined. The provided data indicates a "context-only" state with no active, forming, or invalidated coil structure recorded. Specifically:

• There is no confirmed breakout (Confirmed-Active).

2. The Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None

As of 2026-06-13, there is no named secular thesis attached to BSGM. The name is not currently positioned as a primary beneficiary of a specific macro theme (e.g., "AI Infrastructure" or "Energy Transition") within the StoryStocks framework. Consequently, conviction must be derived strictly from the quality of the technical setup (which is currently absent) and the fundamental business trajectory. No macro thesis should be invented to force a narrative; the name is to be judged on its operational execution and structural readiness alone.

3. The Business

Company Profile: BioSig Technologies, Inc. operates as a medical technology enterprise focused on electrophysiology. The company utilizes a proprietary signal processing platform that merges specialized hardware and software to address challenges in electrophysiological signal acquisition. This technology empowers electrophysiologists to view and analyze vital cardiac signals instantaneously.

Business Model & Partnerships:

• Core Product: PURE EP platforms for cardiac signal analysis.
• Strategic Partnerships:
• Mayo Foundation: A strategic partnership focused on developing advanced AI and machine learning software solutions tailored for PURE EP platforms.
• University of Minnesota: A research agreement targeting the development of new treatments for sympathetic nervous system disorders.
• Financial Context: The financial spine indicates a Forward Consensus EPS (FY1) of -0.17, suggesting the company is currently in a pre-profitability or investment phase.

Evidence of Operations (Source: Earnings Transcript 2026-05-21):

• Revenue Expectations: Management expects "product-related revenue to begin showing through in subsequent quarters as AUM scales, secondary trading infrastructure goes live and our partnership ecosystem activities, an additional distribution channel."
• Product Launches: Management expects Q3 2026 to include the launch of "GLDC and SLVC."
• Infrastructure: The "Orca venue" is expected to go live to provide GLDY option and holders for liquidity, described as a feature "that simply does not exist for traditional gold products."
• Integration: Management anticipates "operating in the coming weeks, subject to some completion of technical integration and operational testing."
• Wintermute Integration: This integration is expected to unlock the ability to mint and redeem GLDY instantly 24/7, reducing purchase and redemption time from T+2 to T+0.
• Market Access: The integration provides access to "$72 billion of U.S. tax-advantaged retirement capital across over 359,000 accounts."
• Asset Metrics: As of the transcript date, GLDY (a tokenized yield-bearing gold asset) has over 3,000 ounces of gold supporting it, representing approximately $14 million in AUM, with over 10 ounces in dividends distributed to holders.
• Market Size: Industry estimates project the tokenized real-world assets market at approximately $16 trillion by 2030.

*Note: There is a significant discrepancy in the provided evidence block. Evidence E1-E8 describes a tokenized gold/crypto infrastructure business (GLDY, Orca, Wintermute), while Evidence E9-E12 describes a medical electrophysiology business (BioSig, PURE EP, Mayo Foundation). As an analyst reasoning on the state of the world as of 2026-06-13, I must report that the company profile cache (E9-E12) identifies the entity as a medical technology enterprise, while the earnings transcript (E1-E8) discusses tokenized gold assets. This suggests either a corporate pivot, a complex holding structure, or a data anomaly that requires clarification. The business description in the "Business" section above reflects the explicit "company_profile_cache" definition (Medical Tech), while the "Earnings" section reflects the tokenized asset narrative.*

4. Archetype and Conviction

Archetype Candidate: — Valuation Context: The financial spine provides a Forward Consensus EPS (FY1) of -0.17. No P/E or P/S multiples are available in the provided data.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; TACTICAL classification).
• Evidence Quality: Mixed/Conflicting. The evidence base contains a fundamental contradiction between the company profile (Medical Tech) and the earnings transcript (Tokenized Gold/Crypto). This creates a significant gap in understanding the actual revenue drivers.
• Setup Readiness: Zero. The price is $6.10, but without a defined entry or stop, no trade can be structured.
• Rerating Potential: Unknown. The market's reaction to the "GLDC and SLVC" launches (expected Q3 2026) and the "Orca venue" is not yet priced in, as the structural setup has not formed.

ATR Context: The current ATR is 10.4% (Extreme). In the StoryStocks canon, extreme ATR (>8%) is associated with the highest historical rate of severe losses. This volatility, combined with the lack of a structural setup, suggests high risk and low structural clarity.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Failure of management to launch GLDC/SLVC in Q3 2026 as expected.
• Failure of the Wintermute integration to reduce redemption times to T+0.
• Clarification that the "Medical Tech" profile is the sole business and the "Tokenized Gold" narrative is a separate, unconsolidated entity or a hallucination in the data feed.

What Would Strengthen:

• Confirmation of the "Orca venue" going live.
• Successful integration with Wintermute and the activation of the $72 billion retirement capital access.
• Clearing of the data discrepancy between the Medical Tech profile and the Tokenized Gold earnings.

Gaps in Evidence:

• Business Clarity: The evidence block presents two mutually exclusive business models (Medical Electrophysiology vs. Tokenized Gold Infrastructure). It is unclear if BioSig Technologies is the parent of a crypto venture, has pivoted, or if the data is misaligned.
• Financials: Only a forward EPS estimate is available; no revenue run-rate, cash burn, or balance sheet details are provided.
• Sector/Industry: The sector and industry are listed as "—" in the setup state, though the profile suggests "Medical Technology" and the transcript suggests "Digital Assets/FinTech."

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key risks: 1) Data integrity failure regarding the company's actual business model. 2) Failure to launch GLDC/SLVC in Q3 2026 as management expects. 3) Extreme volatility leading to rapid drawdown if a structure forms and fails. Sizing hint: Position size should be zero until structural clarity and business model alignment are confirmed. Expected path: Management expects product revenue to show in subsequent quarters and GLDC/SLVC to launch in Q3 2026; the market will likely react to these milestones once the structural setup forms. Expected horizon: Q3 2026 (upon expected product launches).